Research programme: ubiquitin modulators - ProgenraAlternative Names: Deubiquitylating enzyme inhibitors - Progenra; MuRF1 inhibitors - Progenra; P 013222; P 022077; P 13222; P 5091; P005091; P1001; P1002; P1003; Synoviolin/Hrd1 inhibitors - Progenra; ubiquitin isopeptidase inhibitors - Progenra; USP2 inhibitors - Progenra; USP47 inhibitors - Progenra; USP7 inhibitors - Progenra
Latest Information Update: 22 Apr 2016
At a glance
- Originator Progenra
- Class Small molecules
- Mechanism of Action Endopeptidase inhibitors; Ubiquitin-protein ligase inhibitors; USP2 protein inhibitors; USP47 protein inhibitors; USP7 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Multiple myeloma; Muscular atrophy
- Research Rheumatoid arthritis